Somewhat Favorable News Coverage Somewhat Unlikely to Affect Intermolecular (IMI) Stock Price

News headlines about Intermolecular (NASDAQ:IMI) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Intermolecular earned a media sentiment score of 0.24 on Accern’s scale. Accern also gave headlines about the semiconductor company an impact score of 44.9641820109602 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Intermolecular (NASDAQ IMI) opened at $1.34 on Monday. The firm has a market capitalization of $64.96, a PE ratio of -4.96 and a beta of 1.13. Intermolecular has a 52 week low of $0.80 and a 52 week high of $1.65.

ILLEGAL ACTIVITY WARNING: This report was first reported by Community Financial News and is the property of of Community Financial News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at https://www.com-unik.info/2017/12/25/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-intermolecular-imi-stock-price.html.

Intermolecular Company Profile

Intermolecular, Inc provides thin film solutions. The Company’s high productivity combinatorial (HPC) platform, which consists of its tempus processing tools, its automated characterization methods, and its Informatics analysis software, is purpose-built for research and development (R&D) using combinatorial process systems.

Insider Buying and Selling by Quarter for Intermolecular (NASDAQ:IMI)

Receive News & Ratings for Intermolecular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intermolecular and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit